NFG
RLMD icon

Next Financial Group’s Relmada Therapeutics RLMD Stock Holding History

Next Financial Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-306
Closed -$12K – 2406
2020
Q3 		$12K Buy
+306
New +$11.8K ﹤0.01% 1582
2020
Q2 		– Sell
-306
Closed -$10K – 1626
2020
Q1 		$10K Hold
306
– – ﹤0.01% 1532
2019
Q4 		$12K Buy
+306
New +$9.3K ﹤0.01% 1716

Other funds holding RLMD

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Next Financial Group's RLMD Position: Q4 2020 in Review

Next Financial Group sold out of Relmada Therapeutics (RLMD) in Q4 2020, closing a stake of 306 shares — an estimated $12K sold.

Next Financial Group first reported a position in RLMD in Q4 2019 and held it in 3 quarters. The position peaked at $12K in Q3 2020. 80 funds tracked by Wall St. Rank hold RLMD as of Q4 2020.

  • Next Financial Group reported no remaining Relmada Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Next Financial Group sold 306 Relmada Therapeutics shares in Q4 2020, an estimated $12K.
  • Next Financial Group first reported a position in Relmada Therapeutics in Q4 2019 and held it in 3 quarters.
  • Next Financial Group's Relmada Therapeutics position peaked at $12K in Q3 2020.
  • 80 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2020.

Based on Next Financial Group's 13F filing for Q4 2020, filed 5 Feb 2021.